Get the Stockscreener App
1.42
1.43%
0.02
After Hours:
1.45
0.03
+2.11%
Telomir Pharmaceuticals Inc stock is traded at $1.42, with a volume of 214.46K.
It is up +1.43% in the last 24 hours and up +13.60% over the past month.
Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
See More
Previous Close:
$1.40
Open:
$1.42
24h Volume:
214.46K
Relative Volume:
2.09
Market Cap:
$48.82M
Revenue:
-
Net Income/Loss:
$-10.41M
P/E Ratio:
-4.2249
EPS:
-0.3361
Net Cash Flow:
$-3.69M
1W Performance:
-4.05%
1M Performance:
+13.60%
6M Performance:
-9.55%
1Y Performance:
-44.31%
1-Day Range:
$1.33
$1.47
1-Week Range:
$1.33
$1.47
52-Week Range:
$1.05
$3.10
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.42 | 48.13M | 0 | -10.41M | -3.69M | -0.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
426.01 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
744.44 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
783.74 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.51 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.90 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
Telomir (TELO) CEO Aminov issued 7,319,710 shares in TELI acquisition - Stock Titan
Telomir Pharmaceuticals Acquires TELI, Secures Global Rights to Lead Drug Telomir-1 - citybuzz -
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals and Files Form 8-K with Nasdaq Listing - Minichart
Telomir Pharmaceuticals completes TELI Pharmaceuticals acquisition By Investing.com - Investing.com Australia
Telomir Pharmaceuticals Completes TELI Acquisition, Expands Telomir-1 Rights - TipRanks
Telomir completes acquisition of TELI Pharmaceuticals - Investing.com
Telomir Pharmaceuticals completes TELI Pharmaceuticals acquisition - Investing.com
Telomir Completes Acquisition of TELI Pharmaceuticals in All-Stock Deal, Issuing 34.4M Shares - TradingView
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn) - Corsicana Daily Sun
Telomir (NASDAQ: TELO) closes TELI acquisition, issues 34,389,710 shares and adds funding - Stock Titan
Telomir locks up worldwide rights to its lead drug, with $1M now and $4M tied to milestones - Stock Titan
TELO Telomir Pharmaceuticals gains slightly even as Q4 2025 EPS lands far below analyst consensus estimates. - UBND thành phố Hải Phòng
Telomir Pharmaceuticals unveils preclinical data for Telomir-1 at AACR Annual Meeting - Traders Union
Telomir Pharmaceuticals (TELO) Stock: Is It a Compelling Buy (Tumbles Hard) 2026-04-20Analyst Consensus - Cổng thông tin điện tử Tỉnh Sơn La
Telomir Pharmaceuticals (TELO) Stock: Why You Should Hold It (+2.29%) 2026-04-15Most Discussed Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Is Telomir Pharmaceuticals (TELO) Stock Lagging the Market | Price at $1.25, Up 2.46%Continuation Signals - Xã Vĩnh Công
Sentiment Review: Will Telomir Pharmaceuticals Inc outperform small cap indexesPortfolio Risk Summary & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Aug Wrap: How does Telomir Pharmaceuticals Inc compare to its peers2026 Intraday Action & Fast Moving Stock Trade Plans - baoquankhu1.vn
Is Telomir Pharmaceuticals (TELO) Stock Growing Now | Price at $1.30, Up 2.36%Volatility Analysis - Cổng thông tin điện tử tỉnh Lào Cai
TELO SEC FilingsTelomir Pharms 10-K, 10-Q, 8-K Forms - Stock Titan
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer - ACCESS Newswire
Is Telomir Pharmaceuticals (TELO) Stock defensive in downturns | Price at $1.27, Down 3.79%Pro Trader Recommendations - UBND thành phố Hải Phòng
Telomir Pharmaceuticals submits IND in U.S. for Telomir-1 in TNBC - BioWorld News
Telomir Pharmaceuticals Regains Nasdaq Compliance Following 2025 Annual Shareholders Meeting - Minichart
Telomir submits IND application for cancer drug candidate By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Regains Nasdaq Listing Rule Compliance - TipRanks
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) Targeting Advanced Triple-Negative Breast Cancer - Minichart
Telomir Pharmaceuticals Submits IND for Telomir-1 in Advanced Triple-Negative Breast Cancer - National Today
Telomir Pharmaceuticals regains Nasdaq compliance after annual meeting - Investing.com
Nasdaq confirms Telomir (NASDAQ: TELO) back in listing compliance - Stock Titan
Telomir submits IND application for cancer drug candidate - Investing.com
Telomir takes experimental TNBC therapy to FDA for metastatic disease - Stock Titan
Telomir Pharmaceuticals submits IND application to FDA for Telomir-1 in TNBC By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals submits IND application to FDA for Telomir-1 in TNBC - Investing.com
Telomir submits IND for Telomir-1 to treat advanced and metastatic TNBC - TradingView
Telomir Pharmaceuticals (NASDAQ: TELO) files IND for Telomir-1 in advanced TNBC - Stock Titan
Telomir Shareholders Approve Equity Plan and Bylaw Changes - The Globe and Mail
Pullback Watch: Is Telomir Pharmaceuticals Inc stock a buy or sell2026 Weekly Recap & Technical Confirmation Trade Alerts - baoquankhu1.vn
Telomir Pharmaceuticals 2026 Annual Meeting Results: Shareholder Votes, Amended Bylaws, and Incentive Plan Approval - Minichart
Telomir Pharmaceuticals, Inc. unveils Telomir-1 for cellular dysfunction targeting iron and zinc balance - Traders Union
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - Bluffton Today
Telomir Pharmaceuticals shareholders approve acquisition and bylaw changes - Investing.com UK
Telomir Pharmaceuticals (NASDAQ: TELO) clears Teli deal and expands equity incentive plan - Stock Titan
Pharma News: Should I trade or invest in Telomir Pharmaceuticals Inc2026 Earnings & AI Enhanced Trading Alerts - baoquankhu1.vn
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models - ACCESS Newswire
Setup Watch: Is Telomir Pharmaceuticals Inc a cyclical or defensive stockMarket Trend Summary & Community Trade Idea Sharing Platform - baoquankhu1.vn
CEO Moves: Is Telomir Pharmaceuticals Inc stock good for income investors2026 Stock Rankings & Risk Managed Investment Signals - baoquankhu1.vn
Telomir Pharmaceuticals, Inc.: Preclinical Pipeline Targeting Aging and Age-Related Diseases with Novel Small-Molecule Therapeutics - Minichart
Insider Buy: How does Telomir Pharmaceuticals Inc score in quality rankingsMarket Rally & Real-Time Volume Triggers - baoquankhu1.vn
Telomir Pharmaceuticals 2025 10-K: $0 Revenue, $(0.33) EPS on $(10.41)M Net Loss - TradingView
Telomir Pharmaceuticals (NASDAQ: TELO) details 2025 results, Telomir-1 plans and TELI merger - Stock Titan
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):